Stock Events

Stock Events

Paradigm Biopharmaceuticals Limited 

€0.16
19
+€0.02+10.27% Wednesday 13:25

Statistics

Day High
0.15
Day Low
0.15
52W High
0.28
52W Low
0.14
Volume
-
Avg. Volume
-
Mkt Cap
68.99M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.1
-0.07
-0.04
-0.01
Expected EPS
N/A
Actual EPS
-0.031774033974

Financials

-36,083.71%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
58,701.82Revenue
-21.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow P86.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including those in the biopharmaceutical field similar to Paradigm's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biopharmaceutical sector, particularly in developing innovative medicines for various diseases, overlapping with Paradigm's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a competitor due to its strong presence in the biopharmaceutical industry, focusing on antiviral drugs and other treatments that could compete with Paradigm's product offerings.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a competitor because of its broad focus on biotechnological medicines, including treatments for inflammatory diseases, which may overlap with Paradigm's research and development efforts.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes with Paradigm in the biopharmaceutical space, especially in the development of therapies for neurological and neurodegenerative diseases.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a competitor as it operates in the biopharmaceutical sector with a strong emphasis on research and development in areas that could intersect with Paradigm's interests, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company with a wide range of products that could compete with Paradigm's treatments, especially in the biopharmaceutical and vaccine sectors.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a competitor because of its extensive research and development in pharmaceuticals that could directly compete with Paradigm's therapeutic areas, including infectious diseases and oncology.
Novartis
NVS
Mkt Cap237.61B
Novartis is a competitor due to its significant investment in research and development in the healthcare sector, including areas that overlap with Paradigm's focus, such as chronic diseases.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a competitor because it operates broadly in the biopharmaceutical sector, focusing on various therapeutic areas, including respiratory, cardiovascular, and autoimmune diseases, which may compete with Paradigm's portfolio.

About

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Show more...
CEO
ISIN
AU000000PAR5
WKN
000A12FJ4

Listings

F
DE
P86.F
AU
AU
PAR.AU
OTC Link
US
PBIGF

0 Comments

Share your thoughts

FAQ

What is Paradigm Biopharmaceuticals Limited stock price today?▼
The current price of P86.F is €0.16 EUR — it has increased by +10.27% in the past 24 hours. Watch Paradigm Biopharmaceuticals Limited stock price performance more closely on the chart.
What is Paradigm Biopharmaceuticals Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Paradigm Biopharmaceuticals Limited stocks are traded under the ticker P86.F.
Is Paradigm Biopharmaceuticals Limited stock price growing?▼
P86.F stock has risen by +11.81% compared to the previous week, the month change is a +3.87% rise, over the last year Paradigm Biopharmaceuticals Limited has showed a -12.5% decrease.
What is Paradigm Biopharmaceuticals Limited market cap?▼
Today Paradigm Biopharmaceuticals Limited has the market capitalization of 68.99M
When is the next Paradigm Biopharmaceuticals Limited earnings date?▼
Paradigm Biopharmaceuticals Limited is going to release the next earnings report on August 21, 2026.
What were Paradigm Biopharmaceuticals Limited earnings last quarter?▼
P86.F earnings for the last quarter are -0.03 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Paradigm Biopharmaceuticals Limited revenue for the last year?▼
Paradigm Biopharmaceuticals Limited revenue for the last year amounts to 58,701.82 EUR.
What is Paradigm Biopharmaceuticals Limited net income for the last year?▼
P86.F net income for the last year is -21.18M EUR.
When did Paradigm Biopharmaceuticals Limited complete a stock split?▼
The last stock split for Paradigm Biopharmaceuticals Limited was on February 06, 2025 with a ratio of 5:4.